# REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)

> **NCT07302451** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute, Naples** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)

## Interventions

- **COMBINATION_PRODUCT:** Combined Androgen Deprivation Therapy with Relugolix and Image-Guided Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT07302451
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07302451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07302451, "REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07302451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*